Results 41 to 50 of about 4,610 (193)

Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking

Journal of Applied Oral Science, 2015
Objective There is strong evidence of a link between the use of systemic bisphosphonates (BPs) and osteonecrosis of the jaw, especially in cancer patients.
Arezo TARDAST, Reine SJÖMAN, Sigbjørn LØES, Jahan ABTAHI   +3 more
doaj   +1 more source

The awareness and practice of dentists regarding medication-related osteonecrosis of the jaw and its prevention: a cross-sectional survey

BMC Oral Health, 2021
Background Accurate documentation of a patient’s prior medication use and awareness of side effects associated with anti-osteoporotic agents can assist dentists to prevent medication-related osteonecrosis of the jaw. I aimed to determine the awareness of
A. Lum Han
doaj   +1 more source

Rescuing Mitochondrial Dysfunction in Macrophages Prevents Osteonecrosis of the Jaw in Anti‐Resorptive Therapy

Advanced Science, EarlyView.
Schematic model showing the suggested mechanism that ZA induces classical activation of macrophages by impairing mitochondrial biofunction and inhibiting mitochondrial clearance to contribute to the pathological process of BRONJ. RAPA‐loaded nanoparticles ZDPR has shown potential in alleviating BRONJ lesions as well as treating osteoporosis or ...
Hang Zhang, Xin Shen, Haiyang Liu, Xinxi Yuan, Mumin Cao, Xuepeng Lv, Ziji Ling, Songsong Guo, Rongyao Xu, Xiang Li, Hongbing Jiang   +10 more
wiley   +1 more source

Soluble Sema4D From γδ T Cells Exerts Osteoblast Inhibition via Plexin‐B/mTOR Signalling Contributing to Pathogenesis of Bisphosphonate‐Related Osteonecrosis of the Jaws

Cell Proliferation, EarlyView.
Schematic summarizing the pathway of sSema4D from γδ T cells inhibiting osteoblast differentiation in BRONJ. ABSTRACT Bisphosphonate‐related osteonecrosis of the jaw (BRONJ) is a severe complication in patients undergoing long‐term bisphosphonate therapy, while our knowledge on the pathogenesis of BRONJ is far from sufficient.
Lingling Ou, Shijia Qiao, Zhuoyi Liao, Xiner Tan, Hui Huang, Zhiyan Zhou, Ruhui Luo, Weijun Zeng, Yan Yang, Zhongxuan Zhang, Jingchen Chen, Shengli Wang, Yiqin Jiang, Jianlei Hao, Yuqin Shen, Longquan Shao   +15 more
wiley   +1 more source

Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review

Frontiers in Oral Health
IntroductionMedication-related osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to BMA and AA therapies, causing the progressive destruction and death of bone.
Rodolfo Mauceri, Rodolfo Mauceri, Sonia Arduini, Martina Coppini, Martina Coppini, Martina Coppini, Monica Bazzano, Isabel Trujillo, Giuseppina Campisi   +8 more
doaj   +1 more source

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source

Recommendations for bone‐directed therapy in patients with neuroendocrine tumour skeletal metastases at the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting

Internal Medicine Journal, EarlyView.
Abstract The role of anti‐resorptive agents in patients with bone metastases from neuroendocrine neoplasms is unclear. Our aim was to review bone‐specific treatment recommendations by the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting (MDM).
Gayle Radley, Marianne S Elston, Ben Lawrence, Veronica Boyle   +3 more
wiley   +1 more source

Trend Analysis of Medically Related Osteonecrosis of the Jaw in the United States Using US National Inpatient Data From 2016 to 2022

Journal of Public Health Dentistry, EarlyView.
ABSTRACT Objectives This study presents a trend analysis of Medication‐Related Osteonecrosis of the Jaw (MRONJ) using US National Inpatient Sample (NIS) data from 2016 to 2022, providing insights into its epidemiology, comorbidities, and economics.
N. Sheshashayee, M. B. Rao, E. Holmes, D. G. Krishnan   +3 more
wiley   +1 more source

Clinical profile of individuals with bisphosphonate-related osteonecrosis of the jaw: an integrative review

São Paulo Medical Journal, 2020
BACKGROUND: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is still the most prevalent type of osteonecrosis with clinical relevance. In Brazil, bisphosphonate use is high but there is a lack of epidemiological studies on BRONJ. OBJECTIVE: To
Aloizio Premoli Maciel, Reyna Aguilar Quispe, Lázara Joyce Oliveira Martins, Rogério Jardim Caldas, Paulo Sérgio da Silva Santos   +4 more
doaj   +1 more source

Absence of medication-related jaw osteonecrosis after treatment with strontium ranelate in ovariectomized rats

Brazilian Oral Research, 2022
This study aimed to evaluate the potential of strontium ranelate (SR) in medication-related jaw osteonecrosis (MRONJ) after tooth extraction in ovariectomized rats.
Leomar Emanuel de Almeida MECCA, Amanda Regina FISCHBORN, Jessica Daniela ANDREIS, Gabrielle DELFRATE, Tayline MROCZEK, Natália Mariane RIGO, Fábio Brasil de OLIVEIRA, Myrella Lessio CASTRO, Mario TABA JUNIOR, Marcela CLAUDINO, Gilson Cesar Nobre FRANCO   +10 more
doaj   +1 more source